Exscientia Investor Day Presentation Deck
January 2024, 90 slides
  1. Exscientia
  2. Related Decks
  3. Investor Day Presentation Decks
precision designed medicine a a a | Exscientia
forward looking statements | Exscientia
patient first integrated technologies to discover design and develop precision medicines | Exscientia
delivering better pipeline candidates faster | Exscientia
ways we can improve probability of success | Exscientia
positioned us well for long term growth | Exscientia
advancing multiple programmes in | Exscientia
solution integrating knowledge of the patient and drug precision medicine | Exscientia
why are our clinical candidates different | Exscientia
pipeline advancing to the clinic | Exscientia
partnership highlights | Exscientia
our strategy maintains balance sheet strength | Exscientia
supporting slides | Exscientia
patient first is a learning process in ses | Exscientia
expanding technologies enhance value creation | Exscientia
expanded technologies have translated to partnerships | Exscientia
target selection | Exscientia
target generation engine | Exscientia
precision design | Exscientia
why learning beats screening | Exscientia
drug discovery is a learning problem two critical questions | Exscientia
active learning leads to creative breakthroughs | Exscientia
extensive proprietary data generation capabilities | Exscientia
precision objectives for precision design | Exscientia
data and model agnostic | Exscientia
| Exscientia
and scalable toolbox | Exscientia
design of kinase inhibitors | Exscientia
| Exscientia
closing the loop with synthesis testing | Exscientia
driving medicines forward accelerate | Exscientia
our new facility | Exscientia
our studio | Exscientia
synthesis with driven design in mind | Exscientia
connectivity | Exscientia
precision medicine he a | Exscientia
our differentiated process | Exscientia
exalt study first driven functional precision medicine platform to directly improve cancer treatment patient outcomes | Exscientia
exalt study results | Exscientia
expansion of precision medicine platform into solid be | Exscientia
cancer is a heterogenous disease | Exscientia
defining patient selection during drug design | Exscientia
advancing to the clinic | Exscientia
design patient centric drugs with an improved probability of success | Exscientia
inhibitor elucidate phase ongoing beak | Exscientia
elucidate phase ongoing in advanced solid | Exscientia
elucidate phase ongoing in advanced solid | Exscientia
inhibition provides broad oncology opportunity | Exscientia
precision design to effectiveness | Exscientia
our candidate resolves critical design issues | Exscientia
is highly effective in classical models | Exscientia
evaluating the potential of in primary tissue | Exscientia
expanding potential efficacy with rational combinations | Exscientia
proposed of exposure | Exscientia
theta in licensed by phase study ongoing a dis | Exscientia
theta in licensed by in august | Exscientia
large failures on an attractive target | Exscientia
our approach | Exscientia
phase to start in | Exscientia
enabling studies complete | Exscientia
inhibition leads to cell death | Exscientia
inhibition promotes cell differentiation in | Exscientia
inhibition drives to quiescence oes | Exscientia
highly differentiated inhibitor | Exscientia
precision design to therapeutic window | Exscientia
delivering quality candidate against a novel | Exscientia
technology in action precision design of its | Exscientia
active learning enabled breakthrough for | Exscientia
benefit of reversible target engagement on platelets | Exscientia
induces myeloid differentiation | Exscientia
with first line soc and targeted therapies | Exscientia
inhibits growth in | Exscientia
with approved soc and targeted therapies | Exscientia
variability observed in induced cell differentiation a | Exscientia
| Exscientia
summary | Exscientia
malt enabling studies ongoing | Exscientia
potential to avoid key class wide safety concern | Exscientia
malt inhibiting malignant cell signaling in cell lymphomas | Exscientia
precision designed to therapeutic index | Exscientia
avoiding a | Exscientia
malt competitor profiles | Exscientia
technology in action precision design of i | Exscientia
leveraged physics based predictive modelling | Exscientia
inhibits model growth in | Exscientia
inhibits primary human cell proliferation | Exscientia
has a low predicted risk of | Exscientia
malt | Exscientia
summary | Exscientia
| Exscientia
See More
Exscientia
Investor Day Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Inhibitor
Medicine
Drug discovery
Ovarian cancer
Recent decks by Exscientia
Investor Presentation
March 2024
Results
March 2024
Investor Presentation
November 2023
Results
November 2023
See all presentations by Exscientia (14 decks)
Related decks
Nuvectis Pharma
Investor Presentation
January 2024
Nuvectis Pharma
Investor Presentation
August 2023
AstraZeneca
Results
July 2021
Nuvectis Pharma
Investor Presentation
July 2023
AstraZeneca
Results
April 2021
Allarity Therapeutics
Investor Conference
September 2022
Alkermes
Investor Day
March 2021
AstraZeneca
Results
February 2021
Recent decks by Exscientia
See all presentations (14 decks)
Investor Presentation
March 2024
Results
March 2024
Investor Presentation
November 2023
Results
November 2023
Nuvectis Pharma
Investor Presentation
January 2024
Nuvectis Pharma
Investor Presentation
August 2023
AstraZeneca
Results
July 2021
Nuvectis Pharma
Investor Presentation
July 2023
AstraZeneca
Results
April 2021
Allarity Therapeutics
Investor Conference
September 2022
Alkermes
Investor Day
March 2021
AstraZeneca
Results
February 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io